HighTower Advisors
ELTX icon

HighTower Advisors’s Elicio Therapeutics ELTX Stock Holding History

HighTower Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.4K Buy
13,666
+2,500
+22% +$25.1K ﹤0.01% 3724
2026
Q1 		$119K Sell
11,166
-20
-0.2% -$193 ﹤0.01% 3602
2025
Q4 		$89K Buy
+11,186
New +$102K ﹤0.01% 3521
2022
Q4 		– Sell
-1,357
Closed -$12K – 3391
2022
Q3 		$12K Buy
+1,357
New +$14.2K ﹤0.01% 3003

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

HighTower Advisors's ELTX Position: Q2 2026 in Review

HighTower Advisors increased its Elicio Therapeutics (ELTX) stake by 22% in Q2 2026, buying an estimated $25.1K and bringing the position to 13,666 shares worth $53.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3724.

HighTower Advisors first reported a position in ELTX in Q3 2022 and has held it in 4 quarters since. The position peaked at $119K in Q1 2026. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • HighTower Advisors held 13,666 shares of Elicio Therapeutics worth $53.4K as of Q2 2026.
  • HighTower Advisors bought 2,500 Elicio Therapeutics shares in Q2 2026, an estimated $25.1K.
  • Elicio Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3724 holding.
  • HighTower Advisors first reported a position in Elicio Therapeutics in Q3 2022 and has held it in 4 quarters since.
  • HighTower Advisors's Elicio Therapeutics position peaked at $119K in Q1 2026.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.